Arcus Biosciences ((RCUS)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Arcus Biosciences is conducting a Phase 1/1b clinical study titled A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies. The study aims to assess the safety and tolerability of AB801, a new drug, in patients with advanced cancers, and to determine the optimal dose for further trials.
The study is testing AB801, both as a standalone treatment and in combination with Docetaxel, a chemotherapy drug. AB801 is administered orally, while Docetaxel is given via intravenous infusion, targeting advanced malignancies.
This interventional study is non-randomized with a sequential intervention model, focusing on treatment as its primary purpose. There is no masking involved, meaning both researchers and participants know the treatment being administered.
The study began on January 19, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 26, 2025, indicating ongoing recruitment and progress.
This study update could influence Arcus Biosciences’ stock performance positively if the results show promise, potentially boosting investor confidence. It also positions Arcus competitively within the oncology sector, where advancements in cancer treatment are highly valued.
The study is currently ongoing, with further details available on the ClinicalTrials portal.